SB2986 would impose a set of employment and access controls at the Food and Drug Administration to enhance safety and security around the agency’s drug and device review processes. The bill bans employment for nationals of specific foreign countries, requires reporting if an employee has an immediate family member who is such a national, institutes a 10-year limitation on subsequent work for entities based in those countries, and restricts access to drug and device information for certain reviewers.
It defines the terms used and sets out enforcement mechanisms through the Secretary of Health and Human Services and the Commissioner of Food and Drugs.
At a Glance
What It Does
The bill prohibits FDA employment for nationals of China, Russia, or Iran. It requires reporting by employees who have an immediate family member who is a national of one of those countries, with automatic termination for noncompliance. It imposes a 10-year restriction on post-employment work for individuals hired after enactment, and limits data access for reviewers under specific conditions. Definitions for key terms anchor the provisions.
Who It Affects
FDA personnel and contractors, HR and compliance offices, and any staff involved in drug or device application reviews. Also affected are individuals employed after enactment and those with immediate family ties to the restricted countries. The restrictions ripple to entities that hire or collaborate with FDA staff.
Why It Matters
This framework aims to reduce perceived and real security risks in the FDA’s review processes by narrowing who can access sensitive information and by constraining cross-border employment post-employment. It signals a formal risk-management posture for safeguarding drug and device safety in a federal setting.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SB2986 creates a security-forward set of employment rules for the FDA. It bars nationals of China, Russia, and Iran from FDA employment and from performing labor or services for remuneration for the agency.
If an FDA employee has an immediate family member who is a national of one of these countries, they must report that fact through a Commissioner-defined process, and failure to report can lead to termination. The bill also imposes a 10-year post-employment restriction on individuals hired after enactment, prohibiting them from working for or contracting with entities based in a foreign country of concern during that period.
In addition, it restricts data access for certain FDA reviewers: a staff member reviewing drug or device applications may not access information outside their own department if they or an immediate family member has ties to a restricted country, or if they previously worked for a related foreign entity. The definitions section confirms that the foreign countries of concern are China, Russia, and Iran, and defines immediate family as a parent, sibling, or child.
The Five Things You Need to Know
The bill bans FDA employment for nationals of China, Russia, and Iran.
Employees with an immediate family member who is a national of one of these countries must report under a Commissioner-defined process; noncompliance can trigger termination.
There is a 10-year limitation on post-employment work for individuals hired after enactment with respect to foreign-country-based entities.
Existing FDA employees must sign a contractual agreement to accept the new limitation; new hires must sign as a condition of employment.
Data access for reviewers is restricted if the staff member or their immediate family has ties to a foreign country of concern or if the staffer previously worked for a related foreign entity.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
National ban on foreign nationals at FDA
Section 2(a) permanently bars individuals who are nationals of a foreign country of concern from being employed by the FDA or from performing labor or services for remuneration for the agency. The provision targets specific nationalities and creates an absolute employment constraint for those cases.
Reporting by employees with foreign-national family ties
Section 2(b) requires FDA personnel and comparable workers to report if any immediate family member is a national of a foreign country of concern, following a process established by the Commissioner. The Secretary must terminate employment or contractual labor for those who fail to report, creating a strict enforcement trigger tied to disclosure.
10-year post-employment limitation
Section 2(c) limits, for the 10-year period after the date of an employee’s FDA employment, the ability to be employed by or enter into a labor/volunteer agreement with entities based in a foreign country of concern. This applies to individuals hired on or after enactment and is reinforced through contractual and employment conditions.
Data-access limitations for reviewers
Section 2(d) restricts access to drug or device information to the department that employs the reviewer, if the reviewer or an immediate family member has ties to a foreign country of concern or if the reviewer previously worked for a foreign country-based entity. This is a targeted access-control mechanism tied to security considerations.
Definitions
Section 2(e) defines 'foreign country of concern' as the People’s Republic of China, Russia, or Iran, and sets the scope for 'immediate family' as mother, father, sibling, or child. These definitions anchor the scope and enforcement of the preceding provisions.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- FDA security and compliance offices gain clearer authority and standardized processes for enforcement
- HR and personnel security teams within the FDA gain defined obligations and reporting mechanisms
- Domestic health care product companies employing FDA staff benefit from explicit risk controls tied to data access and personnel eligibility
- Public health watchdogs and policymakers gain a more predictable governance framework for safeguarding the integrity of the FDA review process
- National security agencies benefit from a formalized boundary around sensitive information linked to health product regulation
Who Bears the Cost
- FDA HR and IT departments bear new administrative, monitoring, and access-control costs to implement verification and data restrictions
- Biotech and pharmaceutical employers recruiting domestically may experience higher compliance overheads and potential talent-shortages
- Clinical and regulatory programs that rely on cross-border collaboration could face delays or constraints in staffing and data sharing
- Small or mid-sized firms with limited compliance resources bear a disproportionate administrative burden
- Enforcement and legal teams must allocate resources to resolve disputes around reporting and implementation
Key Issues
The Core Tension
Balancing the desire for stricter security with the need to retain a world-class, capable FDA workforce. The act aims to reduce foreign risks but risks hindering talent recruitment, collaboration, and timely drug and device reviews.
The bill imposes a security-first posture on FDA staffing by prohibiting certain foreign-national employment and mandating disclosure and contractual restrictions. It introduces a 10-year post-employment limit for individuals hired after enactment and tightens data-access controls for reviewers under defined risk scenarios.
The provisions depend on a narrow list of countries and a basic definition of immediate family, which may lead to practical challenges in recruitment, dual-national situations, or disputes over who qualifies as immediate family. Implementation hinges on administrative processes established by the Commissioner and the Secretary and may require parallel policies in HR, IT, and legal to avoid inconsistent enforcement.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.